SELLAS Life Sciences Group, Inc.
For the period ended Jun 16, 2026. Filed Jun 18, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 16, 2026 · Filed Jun 18, 2026
Use the contents to explore the available documents and sections.
Contents
Proposal
Proposal 1
The Company’s stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.
| NAME | FOR | WITHHELD | BROKER NON-VOTES |
|---|---|---|---|
| Robert Van Nostrand | 66,490,143 | 4,544,035 | 44,477,593 |
| Jane Wasman | 65,928,448 | 5,105,730 | 44,477,593 |
Proposal 2
The Company’s stockholders ratified the appointment of Baker Tilly US, LLP (as the successor to Moss Adams LLP) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
|---|---|---|---|
| 112,103,701 | 2,126,460 | 1,281,610 | - |
Proposal 3
The Company’s stockholders approved an amendment to the Company’s 2023 Amended and Restated Equity Incentive Plan (the “2023 Equity Plan”) to increase the number of shares of common stock available for sale under the 2023 Equity Plan by 20,000,000.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
|---|---|---|---|
| 42,906,271 | 27,310,386 | 817,521 | 44,477,593 |
Proposal 4
The Company’s stockholders approved the non-binding, advisory resolution on the executive compensation of the Company’s named executive officers.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
|---|---|---|---|
| 52,930,792 | 15,906,732 | 2,196,654 | 44,477,593 |
Proposal 5
The Company’s stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
|---|---|---|---|
| 90,571,992 | 22,200,030 | 2,739,749 | - |
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.